EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer

Seungju Yang, San Hae Im, Ju Yeon Chung, Juhee Lee, Kyung-Hun Lee, Yoo Kyung Kang, Hyun Jung Chung iD

Advanced Science · 2024

DOI: 10.1002/advs.202308763 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Seungju Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CRISPR/Cas system has been introduced as an innovative tool for therapy, however achieving specific delivery to the target has been a major challenge. Here, an antibody‐CRISPR/Cas conjugate platform that enables specific delivery and target gene editing in HER2‐positive cancer is introduced. The CRISPR/Cas system by replacing specific residues of Cas9 with an unnatural amino acid is engineered, that can be complexed with a nanocarrier and bioorthogonally functionalized with a monoclonal antibody targeting HER2. The resultant antibody‐conjugated CRISPR/Cas nanocomplexes can be specifically delivered and induce gene editing in HER2‐positive cancer cells in vitro. It is demonstrated that the in vivo delivery of the antibody‐CRISPR/Cas nanocomplexes can effectively disrupt the plk1 gene in HER2‐positive ovarian cancer, resulting in substantial suppression of tumor growth. The current study presents a useful therapeutic platform for antibody‐mediated delivery of CRISPR/Cas for the treatment of various cancers and genetic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingCRISPR-Cas SystemsHumansMiceAnimalsFemaleCell Line, TumorOvarian NeoplasmsDisease Models, AnimalGene Transfer TechniquesAntibodies, MonoclonalNeoplasmsErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

CRISPR/Casantibody conjugationcancer therapyin vivo gene editingspecific delivery

Substanzen

Antibodies, MonoclonalErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
  • Cancer Research Institute, Seoul National University, Seoul, 03080, Republic of Korea.
  • College of Pharmacy, Gyeongsang National University, Jinju, 52828, Republic of Korea.

ORCID-Profile: Hyun Jung Chung

Förderung

  • National Research Foundation of Korea
  • Ministry of Health and Welfare

Zitieren

APA

Yang, S., Im, S. H., Chung, J. Y., Lee, J., Lee, K. H., Kang, Y. K., & Chung, H. J. (2024). An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer. Advanced Science. https://doi.org/10.1002/advs.202308763

Vancouver

Yang S, Im SH, Chung JY, Lee J, Lee KH, Kang YK, et al. An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer. Advanced Science. 2024. doi:10.1002/advs.202308763

BibTeX
@article{Yang2024,
  author = {Yang, Seungju and Im, San Hae and Chung, Ju Yeon and Lee, Juhee and Lee, Kyung-Hun and Kang, Yoo Kyung and Chung, Hyun Jung},
  title = {An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202308763}
}
Kostenlos starten →